The molecular mechanism of anticancer action of novel octahydropyrazino[2,1-a:5,4-a']diisoquinoline derivatives in human gastric cancer cells [0.03%]
新型八氢吡嗪并二异喹啉衍生物在人胃癌细胞中抗肿瘤作用的分子机制研究
Natalia Pawłowska,Agnieszka Gornowicz,Anna Bielawska et al.
Natalia Pawłowska et al.
Objective The aim of the current study was to examine the anticancer activity and the detailed mechanism of novel diisoquinoline derivatives in human gastric cancer cells (AGS). Methods The viability of AGS cells was measured by MTT (3-(4,5...
Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation [0.03%]
携带EGFR突变的合并小细胞肺癌患者的Afatinib治疗成功案例报告
Midori Tanaka,Hidenobu Ishii,Hayato Moribuchi et al.
Midori Tanaka et al.
Small-cell lung cancer (SCLC) combined with epidermal growth factor receptor (EGFR) mutations is extremely rare, and standard chemotherapeutic strategies have not yet been established. In the present study, we report a case of a 67-year-old...
Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer [0.03%]
贝伐单抗相关的非小细胞肺癌肠穿孔临床预测因素分析
Motohiro Tamiya,Hidekazu Suzuki,Takayuki Shiroyama et al.
Motohiro Tamiya et al.
Background Bevacizumab (Bev) is generally well-tolerated, and Bev-associated intestinal perforation (BAP) is a rare albeit serious side effect in cases of non-small cell lung cancer (NSCLC). Therefore, the present study aimed to identify cl...
Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study [0.03%]
Ifosfamide联合VEGFR抑制剂索拉非尼治疗晚期软组织肉瘤II期临床试验：西班牙肉瘤研究组( GEIS )的研究
Xavier García Del Muro,Joan Maurel,Javier Martínez Trufero et al.
Xavier García Del Muro et al.
Background Sorafenib is a potent targeted-therapy that blockades angiogenesis and has demonstrated activity against some sarcoma subtypes. Preclinical studies suggested that treatment with sorafenib plus cytotoxic agents could result in add...
Clinical Trial
Investigational new drugs. 2018 Jun;36(3):468-475. DOI:10.1007/s10637-018-0583-z 2018
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy [0.03%]
CKD-581（泛组蛋白去乙酰酶抑制剂）治疗标准疗法耐药的淋巴瘤或多发性骨髓瘤患者的Ⅰ期临床研究
Hyungwoo Cho,Dok Hyun Yoon,Kyu-Pyo Kim et al.
Hyungwoo Cho et al.
Background The objective of this study was to assess the safety, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), pharmacokinetics, and anti-tumor efficacy of CKD-581, a novel pan-histone deacetylase inhibitor, in patients wit...
Clinical Trial
Investigational new drugs. 2018 Oct;36(5):877-885. DOI:10.1007/s10637-018-0582-0 2018
A call for improved transparency in financial aspects of clinical trials: a case study of the CREATE-X trial in the New England Journal of Medicine [0.03%]
提高临床试验金融透明度的呼吁——《新英格兰医学杂志》上CREATE-X试验案例分析
Akihiko Ozaki,Morihito Takita,Tetsuya Tanimoto
Akihiko Ozaki
Introduction Globally, laws and guidelines for managing conflict of interest are increasingly implemented to achieve transparency in financial ties between physicians and pharmaceutical and medical device industries, yet little information ...
Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells [0.03%]
Palbociclib联合厄洛替尼协同抗胶质母细胞瘤作用的分子机制：Rb和mTOR信号通路抑制效应相关性研究
Songlin Liu,Yunhong Tang,Xianrui Yuan et al.
Songlin Liu et al.
Genomic studies have established a set of three core-signaling pathways, receptor tyrosine kinase (RTK), p53 and retinoblastoma (Rb) signaling pathways, contributing glioblastoma (GBM) and revealed that dysregulation of at least two pathway...
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies [0.03%]
瑞戈非尼联合卡培他滨治疗一线治失败的晚期/转移性胰腺癌患者的Ⅲ期JANUS-1和JANUS-2研究
Herbert Hurwitz,Eric Van Cutsem,Johanna Bendell et al.
Herbert Hurwitz et al.
Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine improved overall survival (OS) vs capecitabine in a subgroup analysis of patients with metastatic pancreatic cancer and systemic inflammation (C-reactive prot...
Clinical Trial
Investigational new drugs. 2018 Aug;36(4):683-695. DOI:10.1007/s10637-018-0580-2 2018
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer [0.03%]
一种名为MLN0128的双靶点mTOR抑制剂在转移性去势抵抗性前列腺癌患者中的II期临床研究
Laura Graham,Kalyan Banda,Alba Torres et al.
Laura Graham et al.
Background MLN0128 is a first-in-class, dual mTOR inhibitor with potential to outperform standard rapalogs through inhibition of TORC1 and TORC2. This phase II study was designed to assess antitumor activity of MLN0128 in metastatic castrat...
Clinical Trial
Investigational new drugs. 2018 Jun;36(3):458-467. DOI:10.1007/s10637-018-0578-9 2018
PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation [0.03%]
PIK3CA突变使乳腺癌细胞对PI3K抑制和AMPK激活协同治疗敏感化
Songlin Liu,Yunhong Tang,Maomao Yan et al.
Songlin Liu et al.
Breast cancer has been emerging as a most common threat among women, thus many efforts were made to find drugs for fighting breast cancer. So far, PI3K (Phosphatidylinositol-4,5-bisphosphate 3-kinase) inhibitors have been believed to be eff...